196 reports of this reaction
1.2% of all BLINATUMOMAB reports
#18 most reported adverse reaction
ACCIDENTAL EXPOSURE TO PRODUCT is the #18 most commonly reported adverse reaction for BLINATUMOMAB, manufactured by Amgen, Inc. There are 196 FDA adverse event reports linking BLINATUMOMAB to ACCIDENTAL EXPOSURE TO PRODUCT. This represents approximately 1.2% of all 16,815 adverse event reports for this drug.
Patients taking BLINATUMOMAB who experience accidental exposure to product should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ACCIDENTAL EXPOSURE TO PRODUCT is a less commonly reported adverse event for BLINATUMOMAB, but still significant enough to appear in the safety profile.
In addition to accidental exposure to product, the following adverse reactions have been reported for BLINATUMOMAB:
The following drugs have also been linked to accidental exposure to product in FDA adverse event reports:
ACCIDENTAL EXPOSURE TO PRODUCT has been reported as an adverse event in 196 FDA reports for BLINATUMOMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
ACCIDENTAL EXPOSURE TO PRODUCT accounts for approximately 1.2% of all adverse event reports for BLINATUMOMAB, making it a notable side effect.
If you experience accidental exposure to product while taking BLINATUMOMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.